Results 201 to 210 of about 1,231,536 (373)

Application of a cost calculation approach in medical oncology: case of Hassan II university hospital in Morocco. [PDF]

Cost Eff Resour Alloc, 2023
Benabdallah A, Jellouli T.
europepmc   +1 more source

Über 5-FU hinaus: Zukünftige therapeutische Ansätze zur Behandlung des kolorektalen Karzinoms. Zum Vortrag «Beyond 5-FU: Future Directions in the Treatment of Colorectal Cancer»von D.G. Haller (University of Pennsylvania Cancer Center Medical und Hematology-Oncology Outpatient Practice, Hospital of the University of Pennsylvania, Philadelphia, PA

, 2000
Daniel G. Haller
openalex   +1 more source

On the Deluge of Unsubscribed Medical Oncology Information [PDF]

, 2005
David M. Mintzer, Lauren Chmielewski
openalex   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Medical Oncology [PDF]

, 2014
梶浦 新也, 菓子井 達彦
core   +8 more sources

Progressive role of artificial intelligence in treatment decision-making in the field of medical oncology. [PDF]

Front Med (Lausanne)
Bongurala AR, Save D, Virmani A.
europepmc   +1 more source

The European Society for Medical Oncology (ESMO) [PDF]

, 2005

openalex   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Pharmacogenomics and Big Data in medical oncology: developments and challenges. [PDF]

Ther Adv Med Oncol
Marcu LG, Marcu DC.
europepmc   +1 more source

Conference Report: European Society for Medical Oncology Congress 2022. [PDF]

Rare Tumors, 2023
Dogan S.
europepmc   +1 more source